MediWound Files Annual Report on Form 20-F

MediWound Files Annual Report on Form 20-F

YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on March 5, 2026 . The annual report can be accessed on the SEC’s website at http://www.sec.gov , as well as via the Company’s investor relations website at http://ir.mediwound.com .

The Company will provide a hard copy of its annual report on Form 20-F, including its audited financial statements, free of charge, to its shareholders upon request . Request should be directed in writing by email to [email protected] or by post to MediWound Ltd., 42 Hayarkon St ., Yavne 8122745 , Israe l.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid ® , is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx ® , is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter) .